TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Clinically meaningful improvement in the overall response rate (ORR)—the trial’s primary endpoint—was seen across each TIGIT cohort, with a 63.3% ORR reported for group A, a 65.6% ORR seen ...

The number of TIGIT-focused programs in development has nearly doubled in the past few years, growing from 13 in 2017 to 25 in 2020, according to the Cancer Research Institute.

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study ...

iTeos is the latest, but perhaps most high-profile casualty, of a faltering anti-TIGIT landscape. Until this point, only drug candidates had primarily been lost, as opposed to entire biotechs.

TIGIT is an immunosuppressive mediator found on immune cells in the microenvironment of many tumors. Merck and Roche have shown adding anti-TIGIT antibodies to PD-1/L1 checkpoint inhibitors ...

Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences ...

Roche said its experimental cancer immunotherapy directed against TIGIT suffered a second consecutive setback, failing to slow tumor growth in a large study involving the most common lung cancer.

Maybe TIGIT really isn't all that useful as an oncology target, and the absolute best case for it is that it crawls up to clinical significance if you manage to align everything perfectly.

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

TIGIT Inhibitors In Clinical Trials Emerging As Immune Checkpoint Based Targeted Therapy For Cancer Says Kuick ResearchDelhi, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global TIGIT Inhibitor Drug ...

–Detailed Results Will Be Presented on December 20 at 3 pm ET/ 12 pm PT during the ASCO Monthly Plenary Series–. FOSTER CITY, Calif.& HAYWARD, Calif.---- Gilead Sciences, Inc. and Arcus ...